Cited by 336Cannabis and Cannabinoid ResearchMultiple Sclerosis Research StudiesBotulinum Toxin and Related Neurological Disorders

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up

Open access

Zajicek, J P·2005·Journal of Neurology, Neurosurgery & Psychiatry

DOI 10.1136/jnnp.2005.070136PMC PMC1739436

Open this paper in CoChat — free account Open PDF

Abstract

OBJECTIVE: To test the effectiveness and long term safety of cannabinoids in multiple sclerosis (MS), in a follow up to the main Cannabinoids in Multiple Sclerosis (CAMS) study. METHODS: In total, 630 patients with stable MS with muscle spasticity from 33 UK centres were randomised to receive oral Delta(9)-tetrahydrocannabinol (Delta(9)-THC), cannabis extract, or placebo in the main 15 week CAMS study. The primary outcome was change in the Ashworth spasticity scale. Secondary outcomes were the Rivermead Mobility Index, timed 10 metre walk, UK Neurological Disability Score, postal Barthel Index, General Health Questionnaire-30, and a series of nine category rating scales. Following the main study, patients were invited to continue medication, double blinded, for up to 12 months in the follow up study reported here. RESULTS: Intention to treat analysis of data from the 80% of patients followed up for 12 months showed evidence of a small treatment effect on muscle spasticity as measured by change in Ashworth score from baseline to 12 months (Delta(9)-THC mean reduction 1.82 (n = 154, 95% confidence interval (CI) 0.53 to 3.12), cannabis extract 0.10 (n = 172, 95% CI -0.99 to 1.19), placebo -0.23 (n = 176, 95% CI -1.41 to 0.94); p = 0.04 unadjusted for ambulatory status and centre, p = 0.01 adjusted). There was suggestive evidence for treatment effects of Delta(9)-THC on some aspects of disability. There were no major safety concerns. Overall, patients felt that these drugs were helpful in treating their disease. CONCLUSIONS: These data provide limited evidence for a longer term treatment effect of cannabinoids. A long term placebo controlled study is now needed to establish whether cannabinoids may have a role beyond symptom amelioration in MS.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1136/jnnp.2005.070136

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Statistics with Confidence
Smithson, M. J. (2000) · SAGE Publications Ltd eBooks · doi:10.4135/9781446218525 · Cited by 1,871
Cannabidiol and (−)Δ 9 -tetrahydrocannabinol are neuroprotective antioxidants
Hampson, A. J., Grimaldi, M., Axelrod, J., & Wink, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.8268 · Cited by 850
Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial
Zajicek, J., Fox, P., Sanders, H., Wright, D., Vickery, J., Nunn, A., & Thompson, A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14738-1 · Cited by 827
An endogenous cannabinoid (2-AG) is neuroprotective after brain injury
Panikashvili, D., Simeonidou, C., Ben‐Shabat, S., Hanuš, L., Breuer, A., Mechoulam, R., & Shohami, E. (2001) · Nature · doi:10.1038/35097089 · Cited by 752
The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons.
Skaper, S. D., Buriani, A., Toso, R. D., Petrelli, L., Romanello, S., Facci, L., & Leon, A. A. G. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.3984 · Cited by 379
Statistics With Confidence
ASV (1990) · Thorax · doi:10.1136/thx.45.2.160-a · Cited by 356
Cannabinoids inhibit neurodegeneration in models of multiple sclerosis
Pryce, G., Ahmed, Z., Hankey, D. J. R., Jackson, S. J., Croxford, J. L., Pocock, J. M., Ledent, C. A., Petzold, A., Thompson, A. J., Giovannoni, G., et al. (2003) · Brain · doi:10.1093/brain/awg224 · Cited by 345
The perceived effects of smoked cannabis on patients with multiple sclerosis.
Consroe, P., Musty, R., Rein, J. A., Tillery, W., & Pertwee, R. (1997) · European Neurology · doi:10.1159/000112901 · Cited by 329
Controlled randomised crossover trial of the effects of physiotherapy on mobility in chronic multiple sclerosis
Wiles, C. M. (2001) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.70.2.174 · Cited by 222
Neuroprotection in Parkinson's disease: Clinical trials
Stocchi, F., & Olanow, C. W. (2003) · Annals of Neurology · doi:10.1002/ana.10488 · Cited by 102

Show all 11 references

Research works printed but not linked: 2

Hampson AJ, Grimaldi M, Axelrod J, et al. Cannabidiol and (-)delta9- tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci SA 1998;95:8268-73.
Riazi A, Fox P, Vickery J, et al. Developing a patient-based measure of the impact of spasticity in multiple sclerosis. Multiple Sclerosis 2003;9:S151.

Sorted by citations

Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., Keurentjes, J. C., Lang, S., Misso, K., Ryder, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.6358 · Cited by 2,169
Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis
Black, N., Stockings, E., Campbell, G., Tran, L. T., Zagic, D., Hall, W. D., Farrell, M., & Degenhardt, L. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30401-8 · Cited by 564
Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders [RETIRED]
Koppel, B. S., Brust, J. C. M., Fife, T. D., Bronstein, J. M., Youssof, S., Gronseth, G., & Gloss, D. S. (2014) · Neurology · doi:10.1212/wnl.0000000000000363 · Cited by 554
Cannabinoids in medicine: A review of their therapeutic potential
Ben Amar, M. (2006) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2006.02.001 · Cited by 543
When does acute pain become chronic?
Voscopoulos, C., & Lema, M. (2010) · British Journal of Anaesthesia · doi:10.1093/bja/aeq323 · Cited by 473
A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis: Sativex for refractory spasticity in MS
Novotna, A., Mares, J., Ratcliffe, S., Novakova, I., Vachova, M., Zapletalova, O., Gasperini, C., Pozzilli, C., Cefaro, L., Comi, G., et al. (2011) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03328.x · Cited by 475
From Phytocannabinoids to Cannabinoid Receptors and Endocannabinoids: Pleiotropic Physiological and Pathological Roles Through Complex Pharmacology
Ligresti, A., PETROCELLIS, L. D., & Marzo, V. D. (2016) · Physiological Reviews · doi:10.1152/physrev.00002.2016 · Cited by 505
The Pharmacologic and Clinical Effects of Medical Cannabis
Borgelt, L. M., Franson, K. L., Nussbaum, A. M., & Wang, G. S. (2013) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1187 · Cited by 423
Cannabinoids for treatment of chronic non‐cancer pain; a systematic review of randomized trials
Lynch, M. E., & Campbell, F. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.03970.x · Cited by 397
Randomized controlled trial of cannabis‐based medicine in spasticity caused by multiple sclerosis
Collin, C., Davies, P., Mutiboko, I. K., Ratcliffe, S. H., & for the Sativex Spasticity in MS Study Group (2007) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01639.x · Cited by 379
Cannabinoids and Pain: New Insights From Old Molecules
Vučković, S., Srebro, D., Vujović, K. S., Vučetić, Č., & Prostran, M. S. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01259 · Cited by 440
An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee
Huggins, J. P., Smart, T. S., Langman, S., Taylor, L., & Young, T. (2012) · Pain · doi:10.1016/j.pain.2012.04.020 · Cited by 375
Adverse effects of medical cannabinoids: a systematic review
Wang, T., Collet, J.-P., Shapiro, S., & Ware, M. A. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.071178 · Cited by 357
Marijuana Use and Motor Vehicle Crashes
Li, M.-C., Brady, J. E., DiMaggio, C. J., Lusardi, A. R., Tzong, K. Y., & Li, G. (2011) · Epidemiologic Reviews · doi:10.1093/epirev/mxr017 · Cited by 347
Phytocannabinoids as novel therapeutic agents in {CNS} disorders.
Hill, A. J., Williams, C. M., Whalley, B. J., & Stephens, G. J. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.09.002 · Cited by 312
The Therapeutic Potential of Cannabis and Cannabinoids
Grotenhermen, F., & Müller‐Vahl, K. (2012) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2012.0495 · Cited by 309
Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside
Rahn, E. J., & Hohmann, A. G. (2009) · Neurotherapeutics · doi:10.1016/j.nurt.2009.08.002 · Cited by 305
Medical cannabis or cannabinoids for chronic non-cancer and cancer related pain: a systematic review and meta-analysis of randomised clinical trials
Wang, L., Hong, P. J., May, C., Rehman, Y., Oparin, Y., Hong, C. J. H., Hong, B. Y., AminiLari, M., Gallo, L., Kaushal, A., et al. (2021) · BMJ · doi:10.1136/bmj.n1034 · Cited by 318
Cannabinoids in the management of difficult to treat pain
Russo, E. B. (2008) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s1928 · Cited by 300
Cannabinoid CB 2 receptors in human brain inflammation
Benito, C., Tolón, R. M., Pazos, M. R., Núñez, E., Castillo, A. I., & Romero, J. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707505 · Cited by 304
A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis
Collin, C., Ehler, E., Waberzinek, G., Alsindi, Z., Davies, P., Powell, K., Notcutt, W., O'Leary, C., Ratcliffe, S., Nováková, I., et al. (2010) · Neurological Research · doi:10.1179/016164109x12590518685660 · Cited by 283
MUltiple Sclerosis and Extract of Cannabis: results of the MUSEC trial
Zajicek, J., Hobart, J. C., Slade, A. L., Barnes, D., & Mattison, P. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-302468 · Cited by 277
Medical Use of Cannabinoids
Fraguas‐Sánchez, A. I., & Torres‐Suárez, A. I. (2018) · Drugs · doi:10.1007/s40265-018-0996-1 · Cited by 287
Validity, reliability, and clinical importance of change in a 0—10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial
Farrar, J. T., Troxel, A. B., Stott, C. G., Duncombe, P., & Jensen, M. P. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.05.011 · Cited by 252
Medicinal Properties of Cannabinoids, Terpenes, and Flavonoids in Cannabis, and Benefits in Migraine, Headache, and Pain: An Update on Current Evidence and Cannabis Science
Baron, E. P. (2018) · Headache The Journal of Head and Face Pain · doi:10.1111/head.13345 · Cited by 268
Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS)
Ware, M. A., Wang, T., Shapiro, S., Collet, J., Boulanger, A., Esdaile, J. M., GORDON, A. S., Lynch, M. E., Moulin, D. E., & O’Connell, C. M. (2015) · Journal of Pain · doi:10.1016/j.jpain.2015.07.014 · Cited by 249
Cannabinoids in the Treatment of Epilepsy
Friedman, D. J., & Devinsky, O. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1407304 · Cited by 243
The Medicinal Use of Cannabis and Cannabinoids—An International Cross-Sectional Survey on Administration Forms
Hazekamp, A., Ware, M. A., Müller‐Vahl, K., Abrams, D. I., & Grotenhermen, F. (2013) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2013.805976 · Cited by 242
Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial
Corey-Bloom, J., Wolfson, T., Gamst, A., Jin, S., Marcotte, T. D., Bentley, H., & Gouaux, B. (2012) · Canadian Medical Association Journal · doi:10.1503/cmaj.110837 · Cited by 235
Cannabinoid CB1and CB2Receptors and Fatty Acid Amide Hydrolase Are Specific Markers of Plaque Cell Subtypes in Human Multiple Sclerosis
Benito, C., Romero, J. P., Tolón, R. M., Clemente, D., Docagne, F., Hillard, C. J., Guaza, C., & Romero, J. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4814-06.2007 · Cited by 256
Cannabis, Pain, and Sleep: Lessons from Therapeutic Clinical Trials of Sativex®, a Cannabis‐Based Medicine
Russo, E. B., Guy, G. W., & Robson, P. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790150 · Cited by 228
Cannabinoids in health and disease
Kogan, N. M., & Mechoulam, R. (2007) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2007.9.4/nkogan · Cited by 227
Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain
Iskedjian, M., Bereza, B., Gordon, A., Piwko, C., & Einarson, T. R. (2007) · Current Medical Research and Opinion · doi:10.1185/030079906x158066 · Cited by 216
Cannabidiol: A Promising Drug for Neurodegenerative Disorders?
Iuvone, T., Esposito, G., Filippis, D. D., Scuderi, C., & Steardo, L. (2009) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2008.00065.x · Cited by 217
Comprehensive Review of Medicinal Marijuana, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip It's Been …
Baron, E. P. (2015) · Headache The Journal of Head and Face Pain · doi:10.1111/head.12570 · Cited by 219
Review of the neurological benefits of phytocannabinoids
Maroon, J. C., & Bost, J. (2018) · Surgical Neurology International · doi:10.4103/sni.sni_45_18 · Cited by 219
Oromucosal Δ9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: An uncontrolled, open-label, 2-year extension trial
ROG, D., NURMIKKO, T., & YOUNG, C. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.09.013 · Cited by 187
Summary of evidence-based guideline: Complementary and alternative medicine in multiple sclerosis
Yadav, V., Bever, C. T., Bowen, J. D., Bowling, A. C., Weinstock‐Guttman, B., Cameron, M. H., BOURDETTE, D. N., Gronseth, G., & Narayanaswami, P. (2014) · Neurology · doi:10.1212/wnl.0000000000000250 · Cited by 185
The Endocannabinoid System, Cannabinoids, and Pain
Fine, P. G., & Rosenfeld, M. J. (2013) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10129 · Cited by 213
The endocannabinoid system as a target for the treatment of neurodegenerative disease
Scotter, E. L., Abood, M. E., & Glass, M. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00735.x · Cited by 188
Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort
Baron, E. P., Lucas, P., Eades, J., & Hogue, O. (2018) · The Journal of Headache and Pain · doi:10.1186/s10194-018-0862-2 · Cited by 188
Pharmacological management of symptoms in multiple sclerosis: current approaches and future directions
Thompson, A. J., Toosy, A., & Ciccarelli, O. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70249-0 · Cited by 179
The CB2 Cannabinoid Receptor Controls Myeloid Progenitor Trafficking
Palazuelos, J., Davoust, N., Julien, B., Hatterer, E., Aguado, T., Mechoulam, R., Benito, C., Romero, J., Silva, A., Guzmán, M., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m707960200 · Cited by 168
Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper
Otero‐Romero, S., Sastre‐Garriga, J., Comi, G., Hartung, H.-P., Sørensen, P. S., Thompson, A. J., Vermersch, P., Gold, R., & Montalbán, X. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458516643600 · Cited by 163
Cannabinoid Receptors and Endocannabinoids: Role in Neuroinflammatory and Neurodegenerative Disorders
Bisogno, T., & Marzo, V. D. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710793361568 · Cited by 159
A pilot study using nabilone for symptomatic treatment in Huntington's disease
Curtis, A., Mitchell, I., Patel, S., Ives, N. J., & Rickards, H. E. (2009) · Movement Disorders · doi:10.1002/mds.22809 · Cited by 161
Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis
Wade, D. T., Collin, C., Stott, C. G., & Duncombe, P. (2010) · Multiple Sclerosis Journal · doi:10.1177/1352458510367462 · Cited by 151
Treatment for ataxia in multiple sclerosis
Mills, R. J., Yap, L., & Young, C. A. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005029.pub2 · Cited by 141
The endocannabinoid system and its therapeutic exploitation in multiple sclerosis: Clues for other neuroinflammatory diseases
Chiurchiù, V., van der Stelt, M., Centonze, D., & Maccarrone, M. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.10.007 · Cited by 140
Dronabinol Is a Safe Long-Term Treatment Option for Neuropathic Pain Patients
Schimrigk, S., Marziniak, M., Neubauer, C., Kugler, E. M., Werner, G., & Abramov-Sommariva, D. (2017) · European Neurology · doi:10.1159/000481089 · Cited by 136
Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial
Zajicek, J., Ball, S., Wright, D. E., Vickery, J., Nunn, A., Miller, D. H., Cano, M. G., McManus, D., Mallik, S., & Hobart, J. C. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70159-5 · Cited by 132
The Pharmacotherapy of Chronic Pain: A Review
Lynch, M. E., & Watson, C. P. N. (2006) · Pain Research and Management · doi:10.1155/2006/642568 · Cited by 130
The effects of cannabinoid administration on sleep: a systematic review of human studies
Gates, P., Albertella, L., & Copeland, J. (2014) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2014.02.005 · Cited by 127
Control of Spasticity in a Multiple Sclerosis Model is mediated by CB1, not CB2, Cannabinoid Receptors
Pryce, G., & Baker, D. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707003 · Cited by 129
The Effectiveness of Cannabinoids in the Management of Chronic Nonmalignant Neuropathic Pain: A Systematic Review
Boychuk, D., Goddard, G., Mauro, G., & Orellana, M. (2015) · Journal of Oral & Facial Pain and Headache · doi:10.11607/ofph.1274 · Cited by 126
Nabilone as an Adjunctive to Gabapentin for Multiple Sclerosis-Induced Neuropathic Pain: A Randomized Controlled Trial
Turcotte, D., Doupe, M., Torabi, M., Gomori, A., Ethans, K., Esfahani, F., Galloway, K., & Namaka, M. (2015) · Pain Medicine · doi:10.1111/pme.12569 · Cited by 124
Therapeutic potential of cannabis in pain medicine
Hosking, R., & Zajicek, J. (2008) · British Journal of Anaesthesia · doi:10.1093/bja/aen119 · Cited by 124
Therapeutic potential of cannabinoid medicines
Robson, P. (2013) · Drug Testing and Analysis · doi:10.1002/dta.1529 · Cited by 126
Medical Marijuana: Clearing Away the Smoke
Grant, I., Atkinson, J. H., Gouaux, B. D., & Wilsey, B. L. (2012) · The Open Neurology Journal · doi:10.2174/1874205x01206010018 · Cited by 120
Pain and Opioids in Cancer Care: Benefits, Risks, and Alternatives
Bennett, M., Paice, J. A., & Wallace, M. S. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_180469 · Cited by 117
Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis
Serpell, M. G., Notcutt, W. G., & Collin, C. (2012) · Journal of Neurology · doi:10.1007/s00415-012-6634-z · Cited by 113
Cannabinoids and Multiple Sclerosis
Pertwee, R. G. (2007) · Molecular Neurobiology · doi:10.1007/s12035-007-0005-2 · Cited by 112
Cannabis and Cannabinoids for Chronic Pain
Romero-Sandoval, E. A., Kolano, A. L., & Alvarado-Vazquez, P. A. (2017) · Current Rheumatology Reports · doi:10.1007/s11926-017-0693-1 · Cited by 115
Medical Marijuana and Chronic Pain: a Review of Basic Science and Clinical Evidence
Jensen, B., Chen, J. L., Furnish, T. J., & Wallace, M. S. (2015) · Current Pain and Headache Reports · doi:10.1007/s11916-015-0524-x · Cited by 118
Review on clinical studies with cannabis and cannabinoids 2005-2009
Hazekamp, A., & Grotenhermen, F. (2010) · Cited by 110
A brief history of cannabinoid and endocannabinoid pharmacology as inspired by the work of British scientists
Marzo, V. D. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.01.010 · Cited by 115
Cannabinoids and the Brain
Köfalvi, A. (2007) · Springer eBooks · doi:10.1007/978-0-387-74349-3 · Cited by 110
Psychopathological and Cognitive Effects of Therapeutic Cannabinoids in Multiple Sclerosis: A Double-Blind, Placebo Controlled, Crossover Study
Aragona, M., Onesti, E., Tomassini, V., Conte, A., Gupta, S., Gilio, F., Pantano, P., Pozzilli, C., & Inghilleri, M. (2009) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181633497 · Cited by 109
Role of Cannabinoids in Multiple Sclerosis
Zajicek, J., & Apostu, V. I. (2011) · CNS Drugs · doi:10.2165/11539000-000000000-00000 · Cited by 106
Cannabinoids in Chronic Non-Cancer Pain: A Systematic Review and Meta-Analysis
Johal, H. S., Devji, T., Chang, Y., Simone, J. J., Vannabouathong, C., & Bhandari, M. (2020) · Clinical Medicine Insights Arthritis and Musculoskeletal Disorders · doi:10.1177/1179544120906461 · Cited by 105
Pharmacogenetics of chronic pain management
Kapur, B. M., Lala, P., & Shaw, J. L. V. (2014) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2014.05.065 · Cited by 105
The Toxicology of Cannabis and Cannabis Prohibition
Grotenhermen, F. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790151 · Cited by 101
Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review
Lakhan, S. E., & Rowland, M. (2009) · BMC Neurology · doi:10.1186/1471-2377-9-59 · Cited by 103
Cannabis and Its Derivatives: Review of Medical Use
Leung, L. (2011) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2011.04.100280 · Cited by 102
Effects of cannabis on cognitive function in patients with multiple sclerosis
Honarmand, K., Tierney, M. C., O'Connor, P. W., & Feinstein, A. (2011) · Neurology · doi:10.1212/wnl.0b013e318212ab0c · Cited by 101
Scientific Opinion on the risks for human health related to the presence of tetrahydrocannabinol (THC) in milk and other food of animal origin
(CONTAM), E. P. O. C. I. T. F. C. (2015) · EFSA Journal · doi:10.2903/j.efsa.2015.4141 · Cited by 98
Narrative review of the safety and efficacy of marijuana for the treatment of commonly state-approved medical and psychiatric disorders
Belendiuk, K. A., Baldini, L., & Bonn‐Miller, M. O. (2015) · Addiction Science & Clinical Practice · doi:10.1186/s13722-015-0032-7 · Cited by 96
Cannabinoid derivatives and the pharmacological management of pain
Lessa, M. A., Cavalcanti, I. L., & Figueiredo, N. V. (2016) · Revista Dor · doi:10.5935/1806-0013.20160012 · Cited by 104
Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis
Croxford, J. L., Pryce, G., Jackson, S. J., Ledent, C. A., Giovannoni, G., Pertwee, R. G., Yamamura, T., & Baker, D. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2007.10.024 · Cited by 94
Role of Cannabinoids in the Treatment of Pain and (Painful) Spasticity
Karst, M., Wippermann, S., & Ahrens, J. (2010) · Drugs · doi:10.2165/11585260-000000000-00000 · Cited by 91
Cannabinoids for Treatment of MS Symptoms: State of the Evidence
Rice, J., & Cameron, M. H. (2018) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-018-0859-x · Cited by 91
Abnormalities in the cerebrospinal fluid levels of endocannabinoids in multiple sclerosis
Filippo, M. D., Pini, L. A., Pelliccioli, G. P., Calabresi, P., & Sarchielli, P. (2008) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.139071 · Cited by 89
A Review of Herbal Therapy in Multiple Sclerosis
Mojaverrostami, S., Bojnordi, M. N., Ghasemi‐Kasman, M., Ebrahimzadeh, M. A., & Hamidabadi, H. G. (2018) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2018.066 · Cited by 90
Dark Classics in Chemical Neuroscience: Δ 9 -Tetrahydrocannabinol
Banister, S. D., Arnold, J. C., Connor, M. A., Glass, M., & McGregor, I. S. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00651 · Cited by 89
From endocannabinoid profiling to ‘endocannabinoid therapeutics’
Ligresti, A., Petrosino, S., & Marzo, V. D. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.04.615 · Cited by 88
Cannabis use in people with Parkinson’s disease and Multiple Sclerosis: A web-based investigation
Kindred, J. H., Li, K., Ketelhut, N. B., Proessl, F., Fling, B. W., Honce, J. M., Shaffer, W. R., & Rudroff, T. (2017) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2017.07.002 · Cited by 81
Wirksamkeit, Verträglichkeit und Sicherheit von Cannabinoiden bei neuropathischen Schmerzsyndromen: Eine systematische Übersichtsarbeit von randomisierten, kontrollierten Studien
Petzke, F., Enax-Krumova, E. K., & Häuser, W. (2016) · Der Schmerz · doi:10.1007/s00482-015-0089-y · Cited by 80
Interaction of neurotransmitters and neurochemicals with lymphocytes
Kerage, D., Sloan, E. K., Mattarollo, S. R., & McCombe, P. (2019) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2019.04.006 · Cited by 82
The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis
Ball, S., Vickery, J., Hobart, J. C., Wright, D., Green, C., Shearer, J., Nunn, A., Cano, M. G., MacManus, D. G., Miller, D. H., et al. (2015) · Health Technology Assessment · doi:10.3310/hta19120 · Cited by 78
Novel Δ9‐tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects
Klumpers, L. E., Beumer, T. L., van Hasselt, J. G. C., Lipplaa, A., Karger, L. B., Kleinloog, D., Freijer, J. I., de Kam, M. L., & van Gerven, J. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04164.x · Cited by 78
An Open‐Label Comparison of Nabilone and Gabapentin as Adjuvant Therapy or Monotherapy in the Management of Neuropathic Pain in Patients with Peripheral Neuropathy
Bestard, J. A., & Toth, C. C. (2011) · Pain Practice · doi:10.1111/j.1533-2500.2010.00427.x · Cited by 76
The Future of Cannabinoids as Analgesic Agents: A Pharmacologic, Pharmacokinetic, and Pharmacodynamic Overview
McCarberg, B. H., & Barkin, R. L. (2007) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3180a5e581 · Cited by 76
Brain Innate Immunity in the Regulation of Neuroinflammation: Therapeutic Strategies by Modulating CD200-CD200R Interaction Involve the Cannabinoid System
Hernangómez, M., Carrillo-Salinas, F. J., Mecha, M., Correa, F., Mestre, L., Loría, F., Feliú, A., Docagne, F., & Guaza, C. (2014) · Current Pharmaceutical Design · doi:10.2174/1381612820666140130202911 · Cited by 77
Clinical Practice Guidelines for Cannabis and Cannabinoid-Based Medicines in the Management of Chronic Pain and Co-Occurring Conditions
Bell, A. D., MacCallum, C., Margolese, S., Walsh, Z., Wright, P., Daeninck, P. J., Mandarino, E., Lacasse, G., Kaur Deol, J., de Freitas, L., et al. (2024) · Cannabis & Cannabinoid Research · doi:10.1089/can.2021.0156 · Cited by 78
Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects
de Lago, E., Moreno‐Martet, M., Cabranes, A., Ramos, J. A., & Fernández‐Ruíz, J. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.01.030 · Cited by 76
Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis
Filippini, G., Minozzi, S., Borrelli, F., Cinquini, M., & Dwan, K. (2022) · Cochrane Database Systematic Reviews · doi:10.1002/14651858.cd013444.pub2 · Cited by 75
Symptomatic treatment and management of multiple sclerosis
Toosy, A., Ciccarelli, O., & Thompson, A. J. (2014) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52001-2.00023-6 · Cited by 79
Nocebo effects in multiple sclerosis trials: a meta-analysis
Papadopoulos, D., & Mitsikostas, D. (2010) · Multiple Sclerosis Journal · doi:10.1177/1352458510370793 · Cited by 73
Cannabinoid Receptors: A brief history and "what's hot".
Graham, E. S. (2009) · Frontiers in bioscience · doi:10.2741/3288 · Cited by 71
Cannabinoids: new promising agents in the treatment of neurological diseases.
Giacoppo, S., Mandolino, G., Galuppo, M., Bramanti, P., & Mazzon, E. (2014) · Molecules · doi:10.3390/molecules191118781 · Cited by 79

Authors: Zajicek, J. P.
Affiliations: University of Plymouth (GB)
Corresponding author: Zajicek, J P
ORCID: Zajicek, J P
Venue: Journal of Neurology, Neurosurgery & Psychiatry
Publisher: BMJ
Published: 2005-12-01
Volume: 76
Issue: 12
Pages: 1664-1669
ISSN: 0022-3050 (ISSN-L)
DOI: 10.1136/jnnp.2005.070136
PMC: PMC1739436
OpenAlex: W2031114852
Cited by: 335
References: 11
Citations by year: 2026: 5 · 2025: 23 · 2024: 16 · 2023: 6 · 2022: 6 · 2021: 8 · 2020: 15 · 2019: 12 · 2018: 16 · 2017: 20 · 2016: 10 · 2015: 19 · 2014: 22 · 2013: 16 · 2012: 20
FWCI: 14.25
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Neurology Neurosurgery & Psychiatry (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
UCL Discovery (University College London) (submittedVersion)
HighWire Press Open Archive (submittedVersion)
Funders: Medical Research Council
Topics: Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
Health Sciences › Medicine › Clinical Neurology › Botulinum Toxin and Related Neurological Disorders
Keywords: multiple sclerosis, cannabinoids, delta-9-tetrahydrocannabinol, cannabis extracts, spasticity, long-term safety, disability, mobility (physical function), spasticity management
MeSH terms: Administration, Oral, Adolescent, Adult, Cannabis, Double-Blind Method, Female, Persons with Disabilities, Humans, Male, Middle Aged, Multiple Sclerosis, Placebos, Plant Extracts, Severity of Illness Index, Treatment Outcome, Analgesics, Non-Narcotic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks